DTRM BIOPHARMA
Biopharma company conducting clinical trials for cancer research.
DTRM BIOPHARMA
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2011-11-11
Address:
Hangzhou, Zhejiang, China
Country:
China
Total Employee:
1+
Status:
Active
Total Funding:
60 M USD
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Green Pine Capital Partners
Green Pine Capital Partners investment in Series A - DTRM Biopharma
Advantech Capital
Advantech Capital investment in Series A - DTRM Biopharma
More informations about "DTRM Biopharma"
Organization | Zhejiang DTRM Biopharma
Organization Overview. First Clinical Trial. 2016 NCT02891590. First Marketed Drug. None …See details»
DTRM Biopharma - PitchBook
DTRM Biopharma General Information Description. Conductor of clinical trails and developer of oral doublet and triplet therapy technologies. The company is developing a new drug called DTRMWXHS-12, enabling further medical and …See details»
Role of Stem Cell Transplants in Richter’s Transformation - CLL …
Jan 17, 2021 DTRMWXHS-12 (DTRM-12) is a new BTK inhibitor developed by Zhejiang …See details»
DTRM Biopharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . …See details»
DTRM Biopharma - Contacts, Employees, Board Members
Organization. DTRM Biopharma . Connect to CRM . Save . Summary. Financials. People. …See details»
DTRM Biopharma - Products, Competitors, Financials, Employees ...
DTRM Biopharma's latest funding round is Private Equity. How much did DTRM Biopharma …See details»
DTRMWXHS 12 - AdisInsight - Springer
17 Nov 2021 Zhejiang DTRM Biopharma completes a phase I/II trial in Mantle-cell lymphoma …See details»
Zhejiang DTRM Completes $60 Million A Round for US-China …
Jan 5, 2018 Zhejiang DTRM Biopharma announced a $60 million Series A round that will …See details»
Study of a Triple Combination Therapy, DTRM-555, in Patients …
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non …See details»
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in
7 Zhejiang DTRM Biopharma LLC, Plymoth Meeting, Pennsylvania, USA. 8 Memorial Sloan …See details»
Everolimus/DTRMWXHS-12 - Drug Targets, Indications, Patents
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, …See details»
Everolimus/DTRMWXHS-12/Pomalidomide - Drug Targets
This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients …See details»
Simultaneous Global Phase I Studies of a Differentiated BTK …
Dec 8, 2017 Background: Ibrutinib is the first-in-class Bruton's tyrosine kinase inhibitor (BTK) …See details»
A phase Ia/Ib study of a novel BTK inhibitor, DTRMWXHS-12 …
May 30, 2017 In xenograft tumor models, DTRM-555 has shown superior efficacy over single …See details»
Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in ...
Nov 29, 2018 DTRM-555, an optimized mechanism-based combination, consists of the …See details»
Simultaneous Global Phase I Studies of a Differentiated BTK …
Dec 7, 2017 Available plasma levels of DTRM-12 on day 1 in both American and Chinese …See details»
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in …
12), doublet DTRM-505, and then to triplet therapy DTRM-555 (Figure 1). Once 200 mg of …See details»
A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR …
Nov 5, 2020 In phase Ia, an MTD was not reached for DTRM-12 monotherapy; In phase Ib …See details»
Author notes - American Society of Hematology
Nov 13, 2019 Our goal was to determine optimal doses for triplet combination therapy …See details»